Overview
Hepatobiliary and pancreatic imaging
Liver cancer (hepatocellular carcinoma)
Fatty liver, NAFLD, and NASH
Chronic liver disease and cirrhosis
Pancreatic cancer
Technical development in MRI
Quantitative imaging
Liver cancer (hepatocellular carcinoma)
Fatty liver, NAFLD, and NASH
Chronic liver disease and cirrhosis
Pancreatic cancer
Technical development in MRI
Quantitative imaging
Current Appointments & Affiliations
Professor of Radiology
·
2022 - Present
Radiology, Abdominal Imaging,
Radiology
Professor in Medicine
·
2022 - Present
Medicine, Gastroenterology,
Medicine
Member of the Duke Cancer Institute
·
2016 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Geographic and Sex Distribution of LI-RADS Research Globally: A Cross-Sectional Meta-Research Study.
Journal Article Can Assoc Radiol J · April 12, 2026 BACKGROUND: Hepatocellular carcinoma (HCC) has an uneven global distribution and a higher incidence in males. The Liver Imaging Reporting and Data System (LI-RADS) is a standardized imaging framework for HCC diagnosis. It is unclear whether the evidence us ... Full text Link to item CitePerformance of Liver Imaging Reporting and Data System (LI-RADS) nonradiation treatment response algorithm version 2024 on magnetic resonance imaging for transarterial chemoembolization plus systemic therapy in hepatocellular carcinoma.
Journal Article Quant Imaging Med Surg · March 1, 2026 BACKGROUND: The effectiveness of Liver Imaging Reporting and Data System treatment response algorithm version 2024 (LR-TRA v2024) in hepatocellular carcinoma (HCC) patients undergoing locoregional plus systemic combination therapy remains uncertain. We aim ... Full text Link to item CitePerformance of CEUS LI-RADS v2017 major feature combinations: individual patient data meta-analysis.
Journal Article Abdom Radiol (NY) · February 18, 2026 BACKGROUND: The LI-RADS diagnostic algorithm uses imaging features in contrast-enhanced ultrasound (CEUS) to standardize the diagnosis of hepatocellular carcinoma (HCC) in at-risk patients. However, the diagnostic performance of specific major feature comb ... Full text Link to item CiteRecent Grants
Evaluation of Efficacy, Safety and Tolerability of NGM282-PS-231 - NGM08
Clinical TrialPrincipal Investigator · Awarded by NGM Biopharmaceuticals, Inc. · 2024 - 2031Prospective study in human subjects that will undergo multimodality assessment of liver fat and fibrosis. Patients will be identified after undergoing clinically indicated PCCT examinations and would then be recruited for a research MR scan and US sc
Clinical TrialPrincipal Investigator · Awarded by Siemens Medical Solutions USA, Inc. · 2025 - 2029Wake Research WAKE03 - BI 1404-0044 A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with non-cirrhotic non-alcoholic steatohe
Clinical TrialPrincipal Investigator · Awarded by M3 Wake Research Inc · 2025 - 2028View All Grants
Education
University of Iowa ·
2004
M.D.